$PHVS

Nijdam Anna sold $82K of PHVS

Nijdam Anna (Principal Accounting Officer) sold 2,670 shares of Pharvaris N.V. (PHVS) at $30.87 on 2026-06-04.

Original reporting
SEC EDGAR · Nijdam Anna
Published Jun 8, 2026, 6:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 6:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale by a named officer, which can marginally affect sentiment but does not provide operational or financial guidance.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but it is unlikely to drive a fundamental repricing alone.

03

What to watch

Check whether there are additional insider transactions around the same period and whether the insider’s remaining holdings materially change over subsequent filings.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 filing (filed 2026-06-08)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

SEC Form 4 shows PHVS principal accounting officer Nijdam Anna sold 2,670 shares in an open-market transaction for ~$82.4K.

Expected impact

Low near-term impact; any effect is likely short-lived unless selling accelerates or coincides with other negative news.

Evidence & confidence

The filing is a primary-source insider transaction, but it is a relatively small dollar amount and does not indicate a new company event (no guidance, trial, deal, or enforcement action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially with no 10b5-1 plan disclosed.

Key entities

  • Pharvaris N.V.

    Company whose insider transaction was reported on SEC Form 4.

  • Nijdam Anna

    Principal Accounting Officer who sold 2,670 PHVS shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BCRXHigh

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease

BioCryst Pharmaceuticals (BCRX) shares fell 9% on Tuesday, their worst day in over 6 months, after competitor Pharvaris (PHVS) reported positive late-stage trial results for a rare swelling disorder treatment. PHVS shares rose 7% during trading and 3% after-hours. Orladeyo, BioCryst's approved treatment, generated over $2B in revenue since 2020 and is expected to bring in $625M-$645M this year. BioCryst is also developing a second treatment, navenibart, with late-stage data expected in 2027.

$PHVSMedAI 9/10

Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum

Pharvaris (PHVS) presented at the Cantor Fitzgerald conference, highlighting 87% reduction in HAE attacks with deucrictibant in Phase III trials. The company plans an on-demand launch in April 2025 and a prophylaxis filing in the first half of 2025. Management addressed safety concerns and outlined a broad commercial strategy. Shares are up 62% over the past year, with analysts setting price targets between $42 and $79.

$PHVSHighAI 8/10

Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data

Wedbush reaffirmed an Outperform rating and $42 price target for Pharvaris (PHVS) after positive Phase 3 data for deucrictibant XR in preventing hereditary angioedema attacks. The study met primary and secondary endpoints, showing an 83% reduction in attack rate. PHVS reported a Q2 2026 net loss of €47.8M and cash of €318M. The stock is up 7.35% on the day.